Between October 18–21, this website will move to a new web address (from health.gov to odphp.health.gov). During that time, some functions might not work as expected. We appreciate your patience and understanding as we’re working to make this transition as smooth as possible.

U.S. Department of Health and Human Services Office of Disease Prevention and Health Promotion

Fixed-Dose Combinations of Drugs versus Single-Drug Formulations for Treating Pulmonary Tuberculosis

About this resource:

Systematic review

Source: The Cochrane Collaborative

Last Reviewed: May 2016

Workgroups: Global Health Workgroup, Immunization and Infectious Diseases Workgroup

In this Cochrane systematic review, the Cochrane Collaborative found that fixed-dose combinations (FDCs) of anti-tuberculosis medicines may have similar effects as single‐drug formulations for treating people with newly diagnosed pulmonary tuberculosis. The treatment for pulmonary tuberculosis in new patients includes 4 medicines taken by mouth for 6 months, sometimes as FDCs that are combined in 1 tablet and sometimes taken separately as single-drug formulations. Researchers found little to no difference in outcomes for people taking FDCs compared with those taking single-drug formulations.

Read more about this resource

Objectives related to this resource (1)

Reduce tuberculosis cases — IID‑17
Improving

Suggested Citation

1.

Gallardo, C.R., Rigau Comas, D., Valderrama Rodríguez, A., Roqué i Figuls, M., Parker, L.A., Caylà, J. & Bonfill Cosp, X. Fixed‐dose combinations of drugs versus single‐drug formulations for treating pulmonary tuberculosis. Cochrane Database of Systematic Reviews, 2016 (5). DOI: 10.1002/14651858.CD009913.pub2